Unlocking the true power of theranostics
A new chemical platform to find and treat cancer
Radiopharmaceuticals for personalized medicine
We are working to make theranostic treatments more accessible to people with cancer.
Fuzionaire Theranostics was founded to apply a breakthrough in chemistry from Nobel laureate Robert Grubbs’ lab at Caltech to radiopharmaceuticals.
Originally directed to make diagnostic radiopharmaceutical candidates for PET scans, our HetSiFA® library has become a powerful theranostics platform that can make chemically identical PET diagnostics and radioligand therapies at scale.
Theranostics combines PET diagnostics with radioligand therapy for personalized cancer care.
Our solutions make theranostics scalable to reach more people with cancer.
Our HetSiFA® platform
Our platform creates chemically identical diagnostic and therapeutic companions from disease-targeting peptides and other ligands, a feature that enables a personalized therapeutic dose for each cancer patient.
HetSiFA-based diagnostics use the PET nuclide fluorine-18, which offers superior availability, production scalability, and image resolution as compared to gallium-68, often used in theranostics.
HetSiFA-based therapies use the leading alpha- and beta-emitting radionuclides.
Our growing pipeline of cancer theranostics
Our first development program aims to improve the theranostic care of patients with metastatic prostate cancer. We target the gastrin-releasing peptide receptor (GRPR) in prostate cancer with a chemically identical and scalable 18F/ 177Lu theranostic pair. The modularity of our HetSiFA platform enables us to expand our pipeline rapidly and address various pressing needs in oncology.Learn More
We apply Fuzionaire’s core chemistry, based on alkali metal catalysts, to make new theranostics.Read More
Get in touch
If you are interested in learning more about our HetSiFA® platform or pipeline, we want to hear from you.Contact